Welcome to Convergence
Convergence Pharmaceuticals is focused on the development of novel, high value analgesics for the treatment of chronic pain. Innovative approaches to the treatment of chronic pain are desperately needed, most notably because there are a high number of sufferers and current treatments are characterised by poor efficacy and side effects. The Company was formed as an independent biotechnology company in October 2010 following the acquisition of clinical assets from GlaxoSmithKline (GSK), and was acquired by Biogen Idec in February 2015. The Company comprises drug development professionals experienced in designing clinical trial programs, and scientists with world class expertise in ion channel electrophysiology and medicinal chemistry.
Convergence Pharmaceuticals’ pipeline of differentiated clinical-stage compounds targets the points of convergence in chronic pain signalling through modulation of specific ion-channels. Its pipeline of voltage gated sodium channels is unmatched in the industry.